Check out your Company Bowl for anonymous work chats.
We were excited to kick off our #HispanicHeritageMonth celebrations with a networking event and silent auction hosted by our Gileados employee resource group. A special thank you to Gileados for bringing us together to honor the Hispanic community this month and all year long.
As a quality control specialist, Angelica Quimpang helps ensure the production of our cell therapies takes place in a compliant and safe environment. The part of her job she enjoys the most is her team's shared mission to always stay focused on patients.
"It's really rewarding to know that the work we're doing here is going to help change people's lives," says Katie, a Cell Therapy Specialist at Kite. Cell Therapy Specialists are on the front lines of the cell therapy manufacturing process, working with patients’ cells every day.
Kite team members in the Los Angeles area were proud to walk as one blood cancer community at this year’s Light The Night. As the National Presenting Sponsor of Celebration & Community at Light The Night events across the U.S., we join The Leukemia & Lymphoma Society in raising awareness of the need for continued innovation in blood cancer research.
Congratulations to our CEO Christi Shaw on her inclusion in the 2022 Forbes 50 over 50 Entrepreneurs List! These entrepreneurs are recognized for their cutting-edge approach to disrupting their fields, including Christi’s leadership in bringing innovative cancer treatments to more people.
“With autologous CAR T-cell therapy, every single manufacturing batch represents an individual patient. We have a piece of that individual in our hands, and the gravity of that is not lost on any of us." Read more about Jonathan Tsang, Senior Director of Process Development, and his perspective on how Kite approaches challenges and focuses on what matters most: getting CAR T therapies to patients facing difficult-to-treat cancers.
We announced results from our landmark phase 3 study of CAR T-cell therapy versus standard of care in second-line relapsed/refractory large B-cell lymphoma at the American Society of Hematology (ASH) Annual Meeting.
We’re thrilled to welcome all Kite interns starting their journey with us today! Looking forward to having you join us in advancing our focus on the cure.
We're proud to be featured on Glassdoor's 45 Companies Actively Hiring Today list. If you're passionate about changing the future of cancer treatment, come join us!
With our recent U.S. FDA approval, we are excited to continue advancing CAR T-cell therapy for patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
